JP2013506683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013506683A5 JP2013506683A5 JP2012532304A JP2012532304A JP2013506683A5 JP 2013506683 A5 JP2013506683 A5 JP 2013506683A5 JP 2012532304 A JP2012532304 A JP 2012532304A JP 2012532304 A JP2012532304 A JP 2012532304A JP 2013506683 A5 JP2013506683 A5 JP 2013506683A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- corticosteroid
- composition according
- liquid
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 45
- 239000007788 liquid Substances 0.000 claims 17
- 239000003246 corticosteroid Substances 0.000 claims 13
- 239000007787 solid Substances 0.000 claims 12
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 9
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 8
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229960002714 fluticasone Drugs 0.000 claims 4
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 4
- 239000008187 granular material Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 230000002035 prolonged effect Effects 0.000 claims 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 3
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 3
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 claims 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 3
- 229960004436 budesonide Drugs 0.000 claims 3
- 150000001720 carbohydrates Chemical class 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- -1 glycerol formal Chemical compound 0.000 claims 3
- 239000008101 lactose Substances 0.000 claims 3
- 239000000845 maltitol Substances 0.000 claims 3
- 235000010449 maltitol Nutrition 0.000 claims 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 3
- 229940035436 maltitol Drugs 0.000 claims 3
- 229940043353 maltol Drugs 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 3
- 229960001664 mometasone Drugs 0.000 claims 3
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 239000000600 sorbitol Substances 0.000 claims 3
- 235000010356 sorbitol Nutrition 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- 150000005846 sugar alcohols Chemical class 0.000 claims 3
- 239000000811 xylitol Substances 0.000 claims 3
- 235000010447 xylitol Nutrition 0.000 claims 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 3
- 229960002675 xylitol Drugs 0.000 claims 3
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 2
- 230000001070 adhesive effect Effects 0.000 claims 2
- 229940092705 beclomethasone Drugs 0.000 claims 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 2
- 229960003728 ciclesonide Drugs 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 claims 2
- 229960000676 flunisolide Drugs 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 2
- 210000003296 saliva Anatomy 0.000 claims 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 claims 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 claims 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- NFKGQHYUYGYHIS-UHFFFAOYSA-N dibutyl propanedioate Chemical compound CCCCOC(=O)CC(=O)OCCCC NFKGQHYUYGYHIS-UHFFFAOYSA-N 0.000 claims 1
- OUWSNHWQZPEFEX-UHFFFAOYSA-N diethyl glutarate Chemical compound CCOC(=O)CCCC(=O)OCC OUWSNHWQZPEFEX-UHFFFAOYSA-N 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 210000002409 epiglottis Anatomy 0.000 claims 1
- 229940116333 ethyl lactate Drugs 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 210000004704 glottis Anatomy 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 229940074076 glycerol formal Drugs 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002395 mineralocorticoid Substances 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 210000003300 oropharynx Anatomy 0.000 claims 1
- 210000002741 palatine tonsil Anatomy 0.000 claims 1
- 230000000704 physical effect Effects 0.000 claims 1
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 229960002622 triacetin Drugs 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24764209P | 2009-10-01 | 2009-10-01 | |
| US61/247,642 | 2009-10-01 | ||
| PCT/US2010/050860 WO2011041509A1 (en) | 2009-10-01 | 2010-09-30 | Orally administered corticosteroid compositions |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014261068A Division JP6249935B2 (ja) | 2009-10-01 | 2014-12-24 | 経口投与型コルチコステロイド組成物 |
| JP2016199156A Division JP6293230B2 (ja) | 2009-10-01 | 2016-10-07 | 経口投与型コルチコステロイド組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013506683A JP2013506683A (ja) | 2013-02-28 |
| JP2013506683A5 true JP2013506683A5 (https=) | 2013-11-07 |
Family
ID=43823361
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012532304A Pending JP2013506683A (ja) | 2009-10-01 | 2010-09-30 | 経口投与型コルチコステロイド組成物 |
| JP2014261068A Active JP6249935B2 (ja) | 2009-10-01 | 2014-12-24 | 経口投与型コルチコステロイド組成物 |
| JP2016199156A Active JP6293230B2 (ja) | 2009-10-01 | 2016-10-07 | 経口投与型コルチコステロイド組成物 |
| JP2018022869A Pending JP2018100286A (ja) | 2009-10-01 | 2018-02-13 | 経口投与型コルチコステロイド組成物 |
| JP2020028900A Active JP7042015B2 (ja) | 2009-10-01 | 2020-02-24 | 経口投与型コルチコステロイド組成物 |
| JP2022038712A Pending JP2022078275A (ja) | 2009-10-01 | 2022-03-12 | 経口投与型コルチコステロイド組成物 |
| JP2023140872A Pending JP2023166486A (ja) | 2009-10-01 | 2023-08-31 | 経口投与型コルチコステロイド組成物 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014261068A Active JP6249935B2 (ja) | 2009-10-01 | 2014-12-24 | 経口投与型コルチコステロイド組成物 |
| JP2016199156A Active JP6293230B2 (ja) | 2009-10-01 | 2016-10-07 | 経口投与型コルチコステロイド組成物 |
| JP2018022869A Pending JP2018100286A (ja) | 2009-10-01 | 2018-02-13 | 経口投与型コルチコステロイド組成物 |
| JP2020028900A Active JP7042015B2 (ja) | 2009-10-01 | 2020-02-24 | 経口投与型コルチコステロイド組成物 |
| JP2022038712A Pending JP2022078275A (ja) | 2009-10-01 | 2022-03-12 | 経口投与型コルチコステロイド組成物 |
| JP2023140872A Pending JP2023166486A (ja) | 2009-10-01 | 2023-08-31 | 経口投与型コルチコステロイド組成物 |
Country Status (37)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| EP2214679B1 (en) | 2007-11-13 | 2019-03-27 | Meritage Pharma, Inc. | Corticosteroid compositions |
| US20090143343A1 (en) | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US20110097401A1 (en) * | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| NZ624922A (en) | 2009-10-01 | 2016-05-27 | Adare Pharmaceuticals Inc | Orally administered corticosteroid compositions |
| US20120164080A1 (en) * | 2010-06-24 | 2012-06-28 | Meritage Pharma, Inc. | Methods of treatment for esophageal inflammation |
| WO2012020279A1 (en) * | 2010-08-13 | 2012-02-16 | Compagnie Gervais Danone | Product for the upper gastric sphere |
| AU2013259872B2 (en) | 2012-05-08 | 2018-06-28 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| US10716802B2 (en) | 2013-03-15 | 2020-07-21 | The Brigham And Women's Hospital, Inc. | Compounds to modulate intestinal absorption of nutrients |
| MX365513B (es) | 2013-03-15 | 2019-06-06 | Aprecia Pharmaceuticals LLC | Forma de dosificacion de dispersion rapida que contiene levetiracetam. |
| US9339489B2 (en) | 2013-03-15 | 2016-05-17 | Aprecia Pharmaceuticals Company | Rapid disperse dosage form containing levetiracetam |
| GB201308933D0 (en) * | 2013-05-17 | 2013-07-03 | Diurnal Ltd | Paediatric composition |
| US9078853B2 (en) | 2013-06-18 | 2015-07-14 | Cmpd Licensing, Llc | Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| WO2015152517A1 (ko) * | 2014-03-31 | 2015-10-08 | (주)세하바이오 | 항산화 물질 활성 보호를 위한 프롤라민 기반 경구용 필름 제조방법 |
| EP3047846A1 (en) | 2015-01-22 | 2016-07-27 | Ems S.A. | Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus |
| US9980975B2 (en) | 2015-01-22 | 2018-05-29 | Ems S.A. | Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus |
| WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| US9867834B2 (en) | 2015-06-15 | 2018-01-16 | Banner Life Sciences Llc | Non-systemic topical compositions comprising corticosteroids |
| US9877971B2 (en) | 2015-06-15 | 2018-01-30 | Banner Life Sciences Llc | Soft lozenges comprising corticosteroids |
| US10973846B2 (en) | 2015-09-24 | 2021-04-13 | The Brigham And Women's Hospital, Inc. | Water-activated mucoadhesive compositions to reduce intestinal absorption of nutrients |
| CN105412123B (zh) * | 2015-11-06 | 2018-03-13 | 山东省千佛山医院 | 布地奈德联合三唑类抗真菌药物的应用及其产品 |
| US20190217531A1 (en) | 2016-04-06 | 2019-07-18 | Astellas Pharma Inc. | Fast-eluting three-dimensionally molded object, filament for fast-eluting three-dimensionally molded object, and material for fast-eluting three-dimensionally molded object |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| TWI728172B (zh) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| US9999604B2 (en) | 2016-11-17 | 2018-06-19 | Cmpd Licensing, Llc | Compounded solutions of diclofenac and lidocaine and methods |
| US10966946B2 (en) | 2016-11-17 | 2021-04-06 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US11986448B2 (en) | 2016-11-17 | 2024-05-21 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US11737975B2 (en) | 2016-11-17 | 2023-08-29 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US10525025B2 (en) | 2016-11-17 | 2020-01-07 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| CN107595765A (zh) * | 2017-09-22 | 2018-01-19 | 沈阳兴齐眼药股份有限公司 | 一种眼用缓释药物递送系统及其制备方法 |
| WO2019157453A1 (en) * | 2018-02-12 | 2019-08-15 | Trilogy Therapeutics, Inc. | Caspofungin compositions for inhalation |
| SI25373A (sl) | 2018-05-08 | 2018-08-31 | Danijela Marković | Naravna orodisperzibilna tableta |
| CN113271979A (zh) | 2018-10-24 | 2021-08-17 | 费灵有限公司 | 皮质类固醇的粘膜粘附性药物组合物 |
| WO2020227437A1 (en) | 2019-05-06 | 2020-11-12 | Axial Biotherapeutics, Inc. | Sustained release solid dosage forms for modulating the colonic microbiome |
| KR20220074915A (ko) * | 2019-10-01 | 2022-06-03 | 엘로디 파마슈티컬스, 엘.피. | 호산구성 식도염을 치료하고 칸디다증을 감소시키는 방법 |
| KR102275997B1 (ko) * | 2019-11-07 | 2021-07-13 | 연세대학교 산학협력단 | 숙주지향치료를 위한 조성물 |
| JP7720226B2 (ja) * | 2020-11-09 | 2025-08-07 | 東和薬品株式会社 | リバーロキサバン含有口腔内崩壊錠 |
| CN114146089B (zh) * | 2021-12-15 | 2023-06-16 | 安徽贝克生物制药有限公司 | 含依非韦伦、替诺福韦和恩曲他滨的药物组合物 |
| CN119997959A (zh) * | 2022-07-28 | 2025-05-13 | 威斯康星州医药大学股份有限公司 | 用于治疗反流的缓释口服福沙那韦制剂 |
| US11904046B1 (en) * | 2022-11-14 | 2024-02-20 | Eton Pharmaceuticals, Inc. | Hydrocortisone oral liquid formulations |
| CN116869927B (zh) * | 2023-09-06 | 2023-11-10 | 中国医学科学院北京协和医院 | 一种用于治疗嗜酸性食管炎的食道温敏凝胶 |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1170188A (en) | 1967-09-15 | 1969-11-12 | Bayer Ag | N-trityl-imidazoles and salts and uses thereof |
| SE378109B (https=) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| DE2260384C3 (de) * | 1972-12-09 | 1979-11-29 | Hoechst Ag, 6000 Frankfurt | Oral zu applizierendes Corticosteroid-Präparat |
| US4080448A (en) | 1974-11-13 | 1978-03-21 | Mirsky Louis H | Method of treating cellular stress |
| JPS56138200A (en) * | 1980-02-15 | 1981-10-28 | Glaxo Group Ltd | Androstane carbothioate compound |
| SE8004580L (sv) | 1980-06-19 | 1981-12-20 | Draco Ab | Farmaceutisk beredning |
| ATE8790T1 (de) | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
| GB8630913D0 (en) | 1986-12-24 | 1987-02-04 | Glaxo Group Ltd | Pharmaceutical compositions |
| US5446070A (en) | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| ZA892859B (en) | 1988-04-22 | 1989-12-27 | Advanced Polymer Systems Inc | Porous particles in preparations involving immiscible phases |
| GB9002375D0 (en) | 1990-02-02 | 1990-04-04 | Pfizer Ltd | Triazole antifungal agents |
| US5278175A (en) | 1990-02-02 | 1994-01-11 | Pfizer Inc. | Triazole antifungal agents |
| GR1001529B (el) | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
| CA2101773A1 (en) | 1991-01-31 | 1992-08-01 | Toyoichi Tanaka | Interpenetrating-polymer network phase-transition gels |
| US5252337A (en) | 1991-06-25 | 1993-10-12 | Eurand America, Inc. | Controlled release calcium channel blocker microcapsules |
| CA2178473C (en) | 1993-12-20 | 2004-08-24 | Tsi-Zong Tzou | Flunisolide aerosol formulations |
| US5639475A (en) | 1995-02-03 | 1997-06-17 | Eurand America, Incorporated | Effervescent microcapsules |
| SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| GB9517062D0 (en) | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
| US5863910A (en) | 1996-01-12 | 1999-01-26 | Bolonick; Joel | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
| DE19606151C2 (de) | 1996-02-20 | 1999-05-12 | Losan Pharma Gmbh | Ibuprofen-Brausezubereitung sowie Verfahren zur Herstellung derselben |
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| DK0914818T3 (da) * | 1996-06-14 | 2005-07-04 | Kyowa Hakko Kogyo Kk | Intraoralt hurtigt desintegrerbar tablet |
| HUP0000116A3 (en) | 1996-10-01 | 2000-08-28 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture |
| SE9604486D0 (sv) | 1996-12-05 | 1996-12-05 | Astra Ab | Novel formulation |
| GB9707934D0 (en) | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
| IT1291362B1 (it) | 1997-05-13 | 1999-01-07 | Vectorpharma Int | Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi |
| RO118174B1 (ro) | 1997-08-21 | 2003-03-28 | Aventis Pharma Deutschland Gmbh | Lac de unghii şi utilizarea acestuia |
| GB9722426D0 (en) | 1997-10-23 | 1997-12-24 | Univ London Pharmacy | Controlled release formulations |
| CA2322315C (en) | 1998-03-06 | 2008-09-16 | Eurand International S.P.A. | Fast disintegrating tablets |
| SE514128C2 (sv) | 1998-03-17 | 2001-01-08 | Pharmalink Ab | Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit |
| FR2781156B1 (fr) * | 1998-07-20 | 2001-06-29 | Lafon Labor | Composition pharmaceutique destinee notamment a la prevention et au traitement des radiomucites et des chimiomucites |
| US6596298B2 (en) | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
| US6863378B2 (en) | 1998-10-16 | 2005-03-08 | Silverbrook Research Pty Ltd | Inkjet printer having enclosed actuators |
| GB9901819D0 (en) | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
| PL199123B1 (pl) | 1999-04-23 | 2008-08-29 | Leo Pharm Prod Ltd | Niewodna kompozycja farmaceutyczna do stosowania naskórnego i jej zastosowanie |
| GB9915319D0 (en) | 1999-06-30 | 1999-09-01 | Unilever Plc | Hair treatment compositions |
| AU7026800A (en) | 1999-09-11 | 2001-04-17 | Glaxo Group Limited | Pharmaceutical formulation of fluticasone propionate |
| WO2001039749A2 (en) | 1999-11-30 | 2001-06-07 | Panacea Biotec Limited | Fast dissolving composition with prolonged sweet taste |
| AU2001279284A1 (en) | 2000-07-05 | 2002-01-14 | Capricorn Pharma, Inc | Rapid-melt semi-solid compositions, methods of making same and methods of using same |
| KR100446101B1 (ko) * | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
| US7125564B2 (en) | 2001-02-16 | 2006-10-24 | Lavipharm Laboratories, Inc. | Water soluble and palatable complexes |
| US20030050312A1 (en) | 2001-03-12 | 2003-03-13 | Hjorth Thyge Borup | Novel tablets and capsules and a process for its preparation |
| WO2002072150A2 (en) * | 2001-03-13 | 2002-09-19 | Angiotech Pharmaceuticals Inc. | Micellar drug delivery vehicles and uses thereof |
| US6872405B2 (en) * | 2001-05-10 | 2005-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Quick-disintegrating tablet in buccal cavity and manufacturing method thereof |
| MXPA03001838A (es) * | 2001-05-10 | 2003-09-10 | Yamanouchi Pharmaceuticals Co | Tabletas que se desintegran rapidamente en la cavidad bucal y proceso para producir las mismas. |
| US6656493B2 (en) | 2001-07-30 | 2003-12-02 | Wm. Wrigley Jr. Company | Edible film formulations containing maltodextrin |
| FR2831820B1 (fr) | 2001-11-05 | 2004-08-20 | Ethypharm Sa | Comprime orodispersible presentant une grande homogeneite et son procede de preparation |
| US20030206978A1 (en) | 2001-11-29 | 2003-11-06 | Bob Sherwood | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
| US20040009212A1 (en) | 2002-01-30 | 2004-01-15 | Pharma Power Biotec Co. Ltd. | Mucoadhesive thermoresponsive medicament-carrier composition |
| JP4173670B2 (ja) * | 2002-03-08 | 2008-10-29 | 旭化成ファーマ株式会社 | 口腔内崩壊製剤 |
| WO2003087194A1 (en) | 2002-04-05 | 2003-10-23 | United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Polyimides from 2,3,3',4'-biphenyltetracarboxylic dianhydride and aromatic diamines |
| CN1290893C (zh) * | 2002-05-03 | 2006-12-20 | 詹森药业有限公司 | 聚合物微乳状液 |
| AU2003253870A1 (en) | 2002-07-10 | 2004-01-23 | I/O Controls Corporation | Fiber optic control network and related method |
| AU2003270357A1 (en) * | 2002-09-06 | 2004-03-29 | Microbia, Inc. | Inhibitors of fungal invasion |
| WO2004023984A2 (en) | 2002-09-13 | 2004-03-25 | Smith C Steven | Novel composition and method for treatment of upper respiratory conditions |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| KR101099176B1 (ko) | 2003-01-21 | 2011-12-27 | 니뽄 신야쿠 가부시키가이샤 | 구강내 속붕성 정제 |
| JP2006516616A (ja) * | 2003-01-31 | 2006-07-06 | オレクソ・アクチエボラゲット | 即効薬剤組成物 |
| US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
| US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
| US20040265375A1 (en) | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
| US20050009848A1 (en) * | 2003-07-10 | 2005-01-13 | Icn Pharmaceuticals Switzerland Ltd. | Use of antivirals against inflammatory bowel diseases |
| US20060134054A1 (en) | 2003-12-19 | 2006-06-22 | Council Of Scientific And Industrial Research | Polymer composition for pH dependent dissolution behavior and process for preparation thereof |
| BRPI0508612A (pt) | 2004-03-10 | 2007-08-14 | Schering Aktiengellschaft | composições compreendendo drospirenona dispersa molecularmente |
| US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
| ATE353635T1 (de) | 2004-09-09 | 2007-03-15 | Medinfar Produtos Farmaceutico | Schnell wasserdispergierbare und domperidon enthaltende tabletten |
| US20060105038A1 (en) | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
| US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
| US20060292099A1 (en) | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| TW200800142A (en) * | 2005-09-09 | 2008-01-01 | Univ Manitoba | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| JP2007158225A (ja) | 2005-12-08 | 2007-06-21 | Canon Inc | 露光装置 |
| CN1985799B (zh) | 2005-12-19 | 2011-11-09 | 量子高科（北京）研究院有限公司 | 口腔崩解制剂的制备方法 |
| JP2009521523A (ja) * | 2005-12-27 | 2009-06-04 | ジュビラント・オルガノシス・リミテッド | 口中溶解性医薬組成物およびその製造方法 |
| US20080260655A1 (en) * | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| EP1958613A1 (en) | 2007-02-15 | 2008-08-20 | Polichem S.A. | Dermal film-forming liquid formulations for drug release to skin |
| CA2721133C (en) | 2007-04-13 | 2018-11-06 | Somaxon Pharmaceuticals, Inc. | Low-dose doxepin formulations and methods of making and using the same |
| US20090143343A1 (en) * | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US20090123551A1 (en) * | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Gastrointestinal delivery systems |
| US20100216754A1 (en) | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US20150231156A1 (en) | 2007-11-13 | 2015-08-20 | Meritage Pharma, Inc. | Corticosteroid compositions |
| EP2214679B1 (en) | 2007-11-13 | 2019-03-27 | Meritage Pharma, Inc. | Corticosteroid compositions |
| CA2708152A1 (en) * | 2007-12-10 | 2009-06-18 | Eurand, Inc | Orally disintegrating tablets comprising diphenhydramine |
| CN101925349A (zh) | 2007-12-21 | 2010-12-22 | 欧兰德股份有限公司 | 替马西泮的口腔崩解片组合物 |
| JP2009173552A (ja) * | 2008-01-21 | 2009-08-06 | Lion Corp | 胃腸薬 |
| SE533435C2 (sv) | 2008-04-03 | 2010-09-28 | Hm Power Ab | Vridmomentsöverförande arrangemang vid ett vindkraftverk |
| US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
| ES2358158T3 (es) | 2008-07-21 | 2011-05-06 | Dr. Falk Pharma Gmbh | Formulación farmacéutica para el tratamiento del tracto digestivo superior. |
| CN102112114A (zh) | 2008-08-08 | 2011-06-29 | 麦克内尔-Ppc股份有限公司 | 使用三氯蔗糖作为制粒剂 |
| ES2811051T3 (es) | 2008-08-20 | 2021-03-10 | Univ California | Corticosteroides para el tratamiento de enfermedades inflamatorias del tracto gastrointestinal |
| US8696568B2 (en) | 2009-01-15 | 2014-04-15 | Nestec S.A. | Methods, system and kit for diagnosing and treating dysphagia |
| EP2398470A4 (en) | 2009-02-23 | 2013-03-06 | Aptalis Pharmatech Inc | CONTROLLED RELEASE COMPOSITIONS COMPRISING A PROTON PUMP INHIBITOR |
| US20110097401A1 (en) | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| CN102596237A (zh) | 2009-09-07 | 2012-07-18 | Dbv技术公司 | 治疗嗜酸细胞性食管炎的方法 |
| NZ624922A (en) | 2009-10-01 | 2016-05-27 | Adare Pharmaceuticals Inc | Orally administered corticosteroid compositions |
| BR112012012999A2 (pt) | 2009-11-30 | 2019-04-02 | Aptalis Pharmatech, Inc. | Composição farmacêutica, e composição de tablete de desintegração oral (odt) outablete de dispersão rápida (rdt) |
| US20120164080A1 (en) | 2010-06-24 | 2012-06-28 | Meritage Pharma, Inc. | Methods of treatment for esophageal inflammation |
| CA2819663C (en) | 2010-12-02 | 2019-12-24 | Adare Pharmaceuticals, Inc. | Rapidly dispersing granules, orally disintegrating tablets and methods |
| WO2012097436A1 (en) | 2011-01-18 | 2012-07-26 | Toronto Rehabilitation Institute | Method and device for swallowing impairment detection |
| SG191827A1 (en) | 2011-01-28 | 2013-08-30 | Nestec Sa | Apparatuses and methods for diagnosing swallowing dysfunction |
| US20150209432A1 (en) | 2012-07-26 | 2015-07-30 | Lupin Limited | Pharmaceutical compositions of proton pump inhibitor |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| ES2716990T5 (es) | 2013-12-23 | 2023-03-24 | Dr Falk Pharma Gmbh | Formulación farmacéutica optimizada para el tratamiento de cambios inflamatorios del esófago |
| US10294517B2 (en) | 2014-03-17 | 2019-05-21 | Children's Hospital Medical Center | Genetic test for determining susceptibility for eosinophilic esophagitis |
| US10176301B2 (en) | 2014-09-11 | 2019-01-08 | Meritage Pharma, Inc. | Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis |
| US9980975B2 (en) | 2015-01-22 | 2018-05-29 | Ems S.A. | Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus |
| US10869592B2 (en) | 2015-02-23 | 2020-12-22 | Uroviu Corp. | Handheld surgical endoscope |
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| TWI728172B (zh) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| JP2021514513A (ja) | 2018-02-21 | 2021-06-10 | アデア ファーマシューティカルズ，ユーエス，エル．ピー． | 好酸球性食道炎を管理する方法 |
| KR20220074915A (ko) | 2019-10-01 | 2022-06-03 | 엘로디 파마슈티컬스, 엘.피. | 호산구성 식도염을 치료하고 칸디다증을 감소시키는 방법 |
| WO2022020464A1 (en) | 2020-07-21 | 2022-01-27 | Ellodi Pharmaceuticals, L.P. | Modified release rapidly disintegrating compositions of proton pump inhibitors |
| CA3215388A1 (en) | 2021-04-20 | 2022-10-27 | Gina EAGLE | Methods of treating esophageal strictures |
-
2010
- 2010-09-30 NZ NZ624922A patent/NZ624922A/en active IP Right Revival
- 2010-09-30 CA CA2776164A patent/CA2776164C/en active Active
- 2010-09-30 BR BR112012007110-6A patent/BR112012007110A2/pt not_active IP Right Cessation
- 2010-09-30 CN CN201710261488.7A patent/CN107252488A/zh active Pending
- 2010-09-30 UA UAA201413781A patent/UA118087C2/uk unknown
- 2010-09-30 KR KR1020157008676A patent/KR20150043548A/ko not_active Ceased
- 2010-09-30 SG SG10201912526TA patent/SG10201912526TA/en unknown
- 2010-09-30 SG SG10201405886WA patent/SG10201405886WA/en unknown
- 2010-09-30 HR HRP20181266TT patent/HRP20181266T1/hr unknown
- 2010-09-30 MX MX2019005289A patent/MX390734B/es unknown
- 2010-09-30 ES ES10821232.5T patent/ES2683864T3/es active Active
- 2010-09-30 PL PL10821232T patent/PL2482822T3/pl unknown
- 2010-09-30 ES ES18178891T patent/ES2742525T3/es active Active
- 2010-09-30 LT LTEP10821232.5T patent/LT2482822T/lt unknown
- 2010-09-30 EP EP10821232.5A patent/EP2482822B1/en not_active Revoked
- 2010-09-30 PT PT10821232T patent/PT2482822T/pt unknown
- 2010-09-30 EA EA201290171A patent/EA024084B1/ru unknown
- 2010-09-30 CN CN2010800470168A patent/CN102665722A/zh active Pending
- 2010-09-30 DK DK10821232.5T patent/DK2482822T3/en active
- 2010-09-30 PT PT18178891T patent/PT3403654T/pt unknown
- 2010-09-30 PL PL18178891T patent/PL3403654T3/pl unknown
- 2010-09-30 SM SM20190468T patent/SMT201900468T1/it unknown
- 2010-09-30 GE GEAP201012674A patent/GEP20156281B/en unknown
- 2010-09-30 CN CN201611030531.0A patent/CN106421797A/zh active Pending
- 2010-09-30 ME MEP-2019-223A patent/ME03471B/me unknown
- 2010-09-30 RS RSP20191082 patent/RS59241B1/sr unknown
- 2010-09-30 UA UAA201203919A patent/UA108360C2/ru unknown
- 2010-09-30 SG SG10201704847WA patent/SG10201704847WA/en unknown
- 2010-09-30 MX MX2017002757A patent/MX380787B/es unknown
- 2010-09-30 BR BR122022005637-7A patent/BR122022005637B1/pt active IP Right Grant
- 2010-09-30 MY MYPI2012001434A patent/MY171317A/en unknown
- 2010-09-30 DE DE202010018594.7U patent/DE202010018594U1/de not_active Expired - Lifetime
- 2010-09-30 SI SI201031925T patent/SI3403654T1/sl unknown
- 2010-09-30 KR KR1020147017747A patent/KR20140088236A/ko not_active Ceased
- 2010-09-30 EA EA201491358A patent/EA031157B9/ru unknown
- 2010-09-30 SI SI201031731T patent/SI2482822T1/sl unknown
- 2010-09-30 MX MX2012003823A patent/MX364947B/es active IP Right Grant
- 2010-09-30 HU HUE10821232A patent/HUE040119T2/hu unknown
- 2010-09-30 EP EP14184844.0A patent/EP2845595A1/en active Pending
- 2010-09-30 JP JP2012532304A patent/JP2013506683A/ja active Pending
- 2010-09-30 KR KR1020127010779A patent/KR20120104975A/ko not_active Ceased
- 2010-09-30 NZ NZ599401A patent/NZ599401A/en active IP Right Revival
- 2010-09-30 EP EP18178891.0A patent/EP3403654B1/en active Active
- 2010-09-30 HU HUE18178891A patent/HUE046748T2/hu unknown
- 2010-09-30 CA CA3037273A patent/CA3037273C/en active Active
- 2010-09-30 AU AU2010300550A patent/AU2010300550B2/en not_active Ceased
- 2010-09-30 DK DK18178891.0T patent/DK3403654T3/da active
- 2010-09-30 EP EP20192973.4A patent/EP3760187A1/en active Pending
- 2010-09-30 LT LTEP18178891.0T patent/LT3403654T/lt unknown
- 2010-09-30 CA CA2940931A patent/CA2940931C/en active Active
- 2010-09-30 RS RS20180962A patent/RS57595B1/sr unknown
- 2010-09-30 WO PCT/US2010/050860 patent/WO2011041509A1/en not_active Ceased
- 2010-10-01 TW TW104107443A patent/TWI594754B/zh active
- 2010-10-01 US US12/896,005 patent/US8771729B2/en active Active
- 2010-10-01 TW TW099133628A patent/TWI562779B/zh active
- 2010-10-01 PY PY201001041126A patent/PY1041126A/es unknown
- 2010-10-01 UY UY0001032925A patent/UY32925A/es not_active Application Discontinuation
- 2010-10-01 SM SM20180427T patent/SMT201800427T1/it unknown
- 2010-10-01 AR ARP100103589A patent/AR078499A1/es unknown
-
2012
- 2012-03-27 ZA ZA2012/02208A patent/ZA201202208B/en unknown
- 2012-03-29 IL IL218928A patent/IL218928A/en active IP Right Grant
- 2012-03-29 MX MX2022003132A patent/MX2022003132A/es unknown
- 2012-03-29 MX MX2020007226A patent/MX2020007226A/es unknown
- 2012-03-30 CL CL2012000794A patent/CL2012000794A1/es unknown
- 2012-04-04 CO CO12056405A patent/CO6531427A2/es not_active Application Discontinuation
-
2013
- 2013-02-22 ZA ZA2013/01380A patent/ZA201301380B/en unknown
-
2014
- 2014-06-03 US US14/294,660 patent/US9486407B2/en active Active
- 2014-06-23 US US14/311,732 patent/US9387167B2/en active Active
- 2014-12-24 JP JP2014261068A patent/JP6249935B2/ja active Active
-
2015
- 2015-05-20 IL IL238915A patent/IL238915A/en active IP Right Grant
-
2016
- 2016-07-08 US US15/205,390 patent/US9849084B2/en active Active
- 2016-10-07 JP JP2016199156A patent/JP6293230B2/ja active Active
-
2017
- 2017-11-17 US US15/816,154 patent/US10632069B2/en active Active
-
2018
- 2018-02-13 JP JP2018022869A patent/JP2018100286A/ja active Pending
-
2019
- 2019-08-08 HR HRP20191435 patent/HRP20191435T1/hr unknown
- 2019-08-19 CY CY20191100883T patent/CY1122713T1/el unknown
-
2020
- 2020-02-24 JP JP2020028900A patent/JP7042015B2/ja active Active
- 2020-03-17 US US16/821,464 patent/US11246828B2/en active Active
-
2021
- 2021-04-21 US US17/236,295 patent/US11266598B2/en active Active
-
2022
- 2022-01-05 US US17/569,047 patent/US12290598B2/en active Active
- 2022-03-12 JP JP2022038712A patent/JP2022078275A/ja active Pending
-
2023
- 2023-08-31 JP JP2023140872A patent/JP2023166486A/ja active Pending
-
2025
- 2025-04-04 US US19/170,231 patent/US20260021041A1/en active Pending
- 2025-11-28 US US19/403,672 patent/US20260083668A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013506683A5 (https=) | ||
| BR112012007110A2 (pt) | Composição farmacêutica sólida, comprimido de desintegração oral e composição farmacêutica líquida substancialmente não aquosa | |
| US9320746B2 (en) | Method for treating intestinal fibrosis | |
| CN106659751B (zh) | 口腔可分散膜 | |
| US20230157950A1 (en) | Oromucosal film compositions comprising epinephrine particles | |
| Yeruva et al. | Hydrogels for mucosal drug delivery | |
| JP2011503113A (ja) | 胃腸炎の治療用組成物 | |
| RU2681930C2 (ru) | Применение андрографолида в получении фармацевтического препарата для лечения воспалительного заболевания кишечника, микропеллета с андрографолидом для целенаправленной доставки в кишечник и способ ее получения | |
| CN102105139A (zh) | 制备胃滞留剂型的方法 | |
| CN107072952A (zh) | 卡多曲颗粒 | |
| CN109662949A (zh) | 一种醋酸氟氢可的松口腔崩解片及其制备方法 | |
| Senthil et al. | Mucoadhesive slow-release tablets of theophylline: Design and evaluation | |
| WO2024068989A1 (en) | Soft gummy | |
| Chaurasia et al. | Synthetic polymers as biomaterials for the treatment of colon diseases | |
| DK3009130T3 (en) | BECLOMETHASON-DIPROPIONATE COMPOSITIONS IN MODIFIED-RELEASED GASTROR-RESISTANT MICROBUGS | |
| CN104473895A (zh) | 拉莫三嗪口腔崩解缓释片 | |
| WO2020115258A1 (en) | A process for manufacturing reducing sugar-free 5-asa tablet cores | |
| US12440517B2 (en) | Soft gummy | |
| CN105412106A (zh) | 一种含有孟鲁司特钠和地氯雷他定的组合物及其制备方法 | |
| Vageesh | Formulation and Evaluation of Ph Modulated Colon Specific Delivery of Naproxen |